Phase 3 N=105 Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma
Retinoblastoma · Retinal Neoplasm
Primary: Stratum B Response to Window Therapy — 24; 2; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=14 Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma
Unilateral Retinoblastoma
Primary: Number of Patients Experiencing Feasibility Failure — 4 participants
Phase 3 N=30 Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma
Intraocular Retinoblastoma
Primary: Group D Eyes - Treatment Failure Within One Year — 0.52 Probability of treatment failure
Phase 3 N=60 Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
Extraocular Retinoblastoma
Primary: Event-free Survival (EFS) — 88; 83; 28 Probability
Phase 3 N=331 Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma
Intraocular Retinoblastoma
Primary: Event-free Survival (EFS) — 0.9394; 0.9953 Estimated Probability
Phase 3 N=28 Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma
Intraocular Retinoblastoma
Primary: Event-free Survival — 0.65 Proportion of participants
Phase 4 N=26 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma
Retinoblastoma
Primary: Event Free Survival Rate — 7; 4 participants — p=0.034
Phase 2 N=23 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm · Recurrent Childhood Ependymoma · Recurrent Ewing Sarcoma
Primary: Objective Response Rate — 0 percentage of participants
Phase 2 N=34 Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
Oligodendroglioma · Oligoastrocytoma
Primary: Progression-free Survival (PFS) at Six Months (PFS6m) — 21 Percentage of participants
Phase 2 N=92 ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
Disseminated Neuroblastoma · Recurrent Neuroblastoma
Primary: Median Time to Progression as Assessed by Response Evaluation Criteria in Solid Tumors — 45; 42 days
N/A N=29 Calcium Absorption in Patients With Rothmund-Thomson Syndrome
Rothmund-Thomson Syndrome
Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score
Phase 2 N=175 Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
Adult Rhabdomyosarcoma · Childhood Alveolar Rhabdomyosarcoma · Childhood Embryonal Rhabdomyosarcoma
Primary: Feasibility of the Addition of Cixutumumab to Chemotherapy Determined by Patient Enrollment — 0.9390 Proportion of Participants
Phase 4 N=35 VISmodegib for ORbital and Periocular Basal Cell Carcinoma
Carcinoma, Basal Cell
Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants
Phase 1 N=21 Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
CNS Embryonal Tumor, Not Otherwise Specified · Malignant Glioma · Recurrent Atypical Teratoid/Rhabdoid Tumor
Primary: Maximum Tolerated Dose of Ribociclib and Everolimus — 120; 1.2 mg/m^2/day
Phase 1 N=13 INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
Phase 2 N=46 Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Brain Tumors
Primary: Event-free Survival (EFS)
Phase 2 N=62 A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
Prostate Cancer
Primary: Number of Patients Who Achieve a PSA ≤ 4ng/mL After Seven Months of Protocol Treatment in Each Arm — 16; 32 Participants — p=0.87
Phase 3 N=413 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
Brain and Central Nervous System Tumors
Primary: Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors — 79.2; 83.3; 69.6; 86.7 probability of PFS at 2 years — p=0.8001
N/A N=115 Proton Radiation Therapy (RT) for the Treatment of Pediatric Rhabdomyosarcoma
Rhabdomyosarcoma
Primary: Cumulative Incidence (Estimated Percent of Participants) With Grade 3 or Higher Toxicity in Follow-up — 10.9 Percentage of patients
Phase 2 N=20 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
Childhood Hepatocellular Carcinoma · Papillary Thyroid Cancer · Previously Treated Childhood Rhabdomyosarcoma
Primary: Objective Response by RECIST Criteria v 1.1 — 10; 10; 0; 0 participants
Phase 2 N=15 Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
Central Nervous System Tumor, Pediatric · Neuroblastoma
Primary: Therapy Completion Rate — .40 proportion of participants
Phase 2 N=121 IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Retinopathy of Prematurity (ROP)
Primary: Severity of Retinopathy of Prematurity (ROP) as Compared to the Severity of ROP in an Untreated Control Population — 14; 24; 4; 4 participants — p=0.0642
Phase 2 N=9 Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Neuroblastoma · Sarcoma
Primary: Objective Response Rate
Phase 3 N=390 Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Adult Rhabdomyosarcoma · Embryonal Childhood Rhabdomyosarcoma · Embryonal-botryoid Childhood Rhabdomyosarcoma
Primary: Percentage of Patients With Low-risk Rhabdomyosarcoma in Subset 1 Failure Free at 5 Years Following Study Entry — 87; 67 Estimated percentage of participants
Phase 1 N=120 Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity
Retinopathy of Prematurity
Primary: Number of Participants With Successful Treatment of ROP — 11; 14; 21; 9 Participants
Phase 2 N=296 Bevacizumab Against Recurrent Retinal Detachment
Retinal Detachment · Proliferative Vitreoretinopathy
Primary: Number of Participants (or Chart Reviews) With Complete Success of Primary Vitrectomy Surgery — 92; 169 Participants
Phase 1 N=18 TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Neuroblastoma · Medulloblastoma · Relapse
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 14 participants
N/A N=16 Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma
Neuroblastoma
Primary: Percentage of Participants That Are Able to Meet Feasibility Parameters. — 100 percentage of participants
Phase 2 N=87 Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
Adult Rhabdomyosarcoma · Childhood Alveolar Rhabdomyosarcoma · Childhood Pleomorphic Rhabdomyosarcoma
Primary: Event Free Survival Probability — 0.23; 0.43 Probability — p=0.0124
Phase 2 N=44 Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
Retinitis Pigmentosa · Usher Syndrome Type 2 · Usher Syndrome Type 3
Primary: Mean Change in Cone Spacing in Arcminutes (Z Score) of 2 Baseline Values Were Compared With Measurements Obtained at Post-op Month 36 — 1.13; 0.85 Difference in change…